Brain Imaging / MRI · Quantification · Reporting

QuickMind MRICNS Diseases Solution

An AI-assisted imaging platform for the assessment of dementia, Alzheimer’s disease and cerebrovascular disease. Supported MRI sequences provide quantitative brain measurements and structured findings for specialist review.

International product name: QuickMind MRI. Earlier publications and registration documents may use Dr.Brain™.

Coronal, sagittal and axial MRI views with highlighted findings in the original Dr.Brain™ moduleMultiplanar brain MRI

Product Features

Brain Structure Analysis

Quantify regional brain volumes and review cognition-related structures on MRI.

White-Matter Review

Review white-matter findings alongside source images and regional measurements.

English Reporting

Brain Doctor organizes source measurements, reference intervals and review notes in an English report.

Technology Principles

Image Input

Supported imaging sequences are checked for quality before analysis.

AI Quantification

Algorithms identify structures or regions and generate module-specific measurements and maps.

Clinical Review

Specialists review the outputs with source images, clinical history and the relevant evidence.

Explore the technology

Product Experience

Product Quick Tour

Explore original product views. This guided overview does not run an assessment or analyze patient data.

Coronal, sagittal and axial MRI views with highlighted findings in the original Dr.Brain™ module

Review Quantitative Imaging

Explore regional MRI views. Image quality and individual clinical context require specialist review.

From Clinical Assessment to Continued Care

Where It Fits

Memory and brain health clinics
Radiology departments
Neurological imaging assessment

A Structured Workflow

1Check the required sequences and image quality.
2Generate the supported module’s measurements and maps.
3Review segmentation and findings with the original images.
4Integrate verified results with the clinical assessment.

Product Resources

Clinical Evidence and Market Scope

Review study methods, product relevance and limitations in the dedicated evidence library.

Plan Your Deployment

Use this checklist to scope a demonstration and technical evaluation with our team.

Before the Demonstration

Share your country, care setting, intended users and preferred product modules.

During Technical Evaluation

Confirm required imaging sequences, image quality, output formats and any PACS or reporting interfaces.

Before Rollout

Agree on local availability, deployment configuration, data handling, training, support and acceptance criteria.

Integration, hosting location, response times and service terms are confirmed for each project. This page does not promise a specific interface or installation time.

PRODUCT QUESTIONS

Questions About This Solution

What is Dr.Brain™ used for?

QuickMind MRI is the international imaging product name presented on this site. Earlier publications refer to Dr.Brain™. It provides quantitative MRI measurements for clinician-led review; QuickMind VR assessment and training are presented separately.

Explore Product

Does cognitive screening diagnose dementia?

A screening result can help identify people who need further assessment. It is not a standalone dementia diagnosis. Clinical history, examination and appropriate investigations remain part of the diagnostic pathway.

Explore cognitive assessment

What clinical evidence is available for Dr.Brain™?

This collection focuses on quantitative MRI research. The combined MRI and VR study is linked to both products; standalone eye-tracking research is listed under QuickMind VR.

Read component-specific evidence

Where can I view a sample brain health report?

The English Brain Health & Longevity Report shows example regional MRI findings and source notes for clinician-led consultations. It is a sample reporting format, not an individual medical diagnosis.

View the English sample report
GLOBAL COLLABORATION

Build the Future of
Brain Health With Us

We welcome conversations with healthcare providers, research institutions, and international distribution partners.